Member Comments are provided by individuals and reflect their personal opinions only. Under NO circumstances should you act on any advice or opinion posted in this forum. ALWAYS check with your personal physician before taking any action regarding your health! MedHelp International and our partners, sponsors and affiliates have no obligation to monitor any comments posted on this site, or the content and/or accuracy of such exchanges. MedHelp International does not endorse the views of any user.
Idenix drug does very well in study
by andiamo, Jun 12, 2007 12:00AM
7:02AM Idenix Pharma says Valopicitabine combined with standard of care cleared Hepatitis C virus in 72% of patients who completed 12 weeks of treatment (IDIX) 7.23 : Co announces results from a phase II study designed to evaluate triple combination therapy, consisting of valopicitabine, the co's lead drug candidate for the treatment of hepatitis C, pegylated interferon and ribavirin compared to pegylated interferon and ribavirin. This study demonstrated no pharmacokinetic or pharmacodynamic drug-drug interaction between valopicitabine and ribavirin. The triple combination showed consistently higher rates of HCV PCR-negativity, defined as serum HCV RNA levels below 20 copies/mL, compared to the standard of care at every point analyzed in this study. Additionally, the tolerability of the triple combination was satisfactory, with only three discontinuations from the study.
Post Comment
Related Communities
Recent Videos
Related Expert Forums
Recent Activity
Most Popular Trackers
RSS
Expert Activity
Community Members
Popular Groups
WHY are there no responces to this post? Any links to check this out.